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Abstract
The symptom literature in cancer has primarily examined symptom severity, frequency, and 
distress. Assessing cancer patients’ perceptions of symptom importance—how important it is for 
them to see improvement in a symptom following an intervention—and factors influencing these 
judgments would also inform patient-centred care, but this analysis has not been undertaken. This 
qualitative study aimed to identify factors underlying perceptions of symptom importance among 
25 symptomatic metastatic breast cancer (MBC) patients. Participants were recruited from a 
cancer centre in the Midwestern USA. Semi-structured interviews focused on patients’ rationale 
for considering common symptoms (i.e., anxiety, sadness, sleep problems, pain, or fatigue) to be 
important. Thematic analyses revealed five interrelated factors underlying MBC patients’ 
perceptions of symptom importance: activity restriction, concentration difficulties, exacerbation of 
other physical symptoms, symptom-related long-term health concerns, and negative impact on 
their relationships with others. Patients most frequently stated that a physical or psychological 
symptom was important because of the resulting activity restriction. Additionally, some patients 
considered pain to be important because it signalled potential long-term health concerns, such as 
worsening metastatic disease. Findings suggest that clinicians should take into account MBC 
patients’ perceptions of symptom importance and factors underlying these judgments when 
making shared treatment decisions.
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INTRODUCTION
Breast cancer is the leading cause of cancer deaths in women worldwide, accounting for 
521,900 deaths in 2012 alone (American Cancer Society, 2015). Symptoms are highly 
prevalent and undertreated in metastatic breast cancer (MBC) patients and are a major 
source of suffering, impairment, and disability (Aranda et al., 2005; Cleeland et al., 2014; 
Given et al., 2007; Lam et al., 2013; Low & Stanton, 2015; Mosher & Duhamel, 2012; 
Willis et al., 2015). The most prevalent, persistent, and disabling symptoms in this 
population include depression, anxiety, sleep disturbance, pain, and fatigue (Aranda et al., 
2005; Grabsch et al., 2006; Kissane et al., 2004; Koopman et al., 2002; Palesh et al., 2007). 
Research suggests that 36% of MBC patients have depression, anxiety, or both (Grabsch et 
al., 2006). Worsening depression has been associated with negative changes in sleep in MBC 
patients (Palesh et al., 2007), with over 60% reporting one or more types of sleep 
disturbance (Koopman et al., 2002). Sleep problems often co-occur with pain and fatigue, 
with over half of MBC patients reporting significant levels of these symptoms (Aranda et al., 
2005; Cleeland et al., 2014; McGuire & Sheidler, 1992).
Research on symptoms in MBC and other cancer patients has primarily examined symptom 
severity, frequency, and distress (Fan et al., 2007; Willis et al., 2015). A notable gap in this 
research is assessing which symptoms are most important from the patient’s perspective. For 
example, a patient who has daily pain but only occasional fatigue might experience the 
fatigue as more bothersome and debilitating, leading the patient to place greater importance 
on alleviating fatigue than pain. Understanding patients’ priorities with respect to symptom 
improvement is critical for the provision of patient-centred care, which takes into account 
patients’ needs, values, and preferences, and some evidence suggests that it improves health 
care quality, disease outcomes, and patient satisfaction while reducing health care costs 
(Dwamena et al., 2012; Epstein et al., 2010).
Although perceptions of symptom importance have not been studied in cancer patients, these 
perceptions have been assessed in patients with chronic pain conditions (Robinson et al., 
2005). Studies have found that not all patients prioritize improvement in the same 
symptoms; some patients were most interested in pain reduction, whereas others placed 
greater emphasis on improvement of other symptoms, such as fatigue or emotional distress 
(Robinson et al., 2005; Yi et al., 2014; Zeppieri et al., 2012). Not only do patients differ in 
the specific symptoms they consider most important, they also differ in the overall number 
of symptoms they prioritize for improvement. Such differences in number of prioritized 
symptoms may be related to important outcomes. For example, patients with chronic pain 
who rate all symptoms as highly important have been found to experience greater anxiety 
and depressive symptoms (Yi et al., 2014; Zeppieri et al., 2012).
Given their considerable symptom burden, similar findings may be expected in symptomatic 
MBC patient samples. However, some of the factors driving perceptions of symptom 
importance may be unique to MBC patients. For example, some MBC patients may view 
pain as a treatment priority because of its association with disease metastasis. Understanding 
MBC patients’ symptom priorities will enable the design of patient-centred interventions 
that promote shared treatment decision-making between patients and providers. Therefore, 
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the goal of this qualitative study was to identify factors underlying symptomatic MBC 
patients’ perceptions of the importance of seeing improvement in symptoms following an 
intervention. Our analysis focused on the importance of reducing anxiety, sadness, sleep 
problems, pain, and fatigue because they are among the most common and disabling 
symptoms in this population (Aranda et al., 2005; Grabsch et al., 2006; Palesh et al., 2007; 
Willis et al., 2015).
METHODS
Recruitment
Women with stage IV breast cancer were recruited from an academic cancer centre in 
Indianapolis, Indiana between May and August 2015. The cancer centre’s institutional 
review board approved all study procedures. Following oncologist approval, letters inviting 
study participation and consent forms were mailed to patients. Then research assistants 
called patients to screen them for eligibility and complete the informed consent process. 
Eligible patients were at least 18 years of age and fluent in English. Patients were excluded 
from study participation if they made three or more errors on a validated 6-item cognitive 
screener (Callahan et al., 2002). At the time of enrolment, participants received a brochure 
providing contact information for mental health services at the cancer centre.
Data collection
Consenting patients completed a standardized telephone assessment of their physical and 
psychological symptoms and perceptions of symptom importance. Patients who endorsed a 
usual level of 4 or higher on a 0 to 10 scale for anxiety, sadness, sleep problems, pain, or 
fatigue on the Patient Centered Outcomes Questionnaire (PCOQ; Robinson et al., 2005) 
were invited to participate in an in-depth, semi-structured telephone interview. This 
interview explored factors underlying patients’ perceptions of symptom importance (i.e., the 
degree to which symptoms were viewed as treatment priorities).
Interviews were conducted within 3 weeks of the standardized assessment by a female 
doctoral student in clinical psychology who had experience conducting qualitative 
interviews with cancer populations. Interviews ranged from 25 to 55 minutes and were 
digitally recorded. First, the interviewer selected the symptom (i.e., anxiety, sadness, sleep 
problems, pain, or fatigue) with the highest importance rating and asked the patient to 
describe her thoughts when rating the symptom’s importance. If multiple symptoms had the 
highest importance rating, then the patient selected one of these symptoms to begin the 
interview. Subsequently, the patient was asked to indicate how the symptom affected her life. 
The interviewer asked follow-up questions to obtain rich information about factors 
underlying perceived symptom importance. Then the interviewer asked the same set of 
questions regarding the symptom with the second highest importance rating. Again, 
participants selected one symptom for the interview if multiple symptoms met this criterion. 
Patients received a $50 gift card for participating in the interview.
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Patients reported their demographic information during the initial assessment. Patients’ 
medical information (i.e., date of diagnosis and treatments received) was obtained from 
medical records.
Qualitative data analysis
Interviews were transcribed verbatim and imported into Atlas.ti for thematic analysis (Braun 
& Clarke, 2006). This method of qualitative analysis involves identifying, analysing, and 
reporting patterns or themes across a data set. We conducted an inductive thematic analysis 
rather than a theoretical one because the study was descriptive and exploratory (Braun & 
Clarke, 2006). A clinical psychologist who specializes in psycho-oncology and a radiation 
therapist with extensive clinical research experience read all transcripts and generated initial 
codes. The codes were refined as the researchers independently coded the transcripts in 
Atlas.ti and met regularly (i.e., after the first two transcripts and following every four 
transcripts thereafter) to review the codes and resolve differences in coding for each 
transcript. Then the researchers organized coded text into broader themes capturing the 
experiences and perceptions of participants, and then checked these interpretations against 
data across transcripts to ensure that the themes were internally consistent and distinct from 
one another.
RESULTS
Participant characteristics
Of the 107 MBC patients who received mailed information about this study, 85 (79%) 
completed the screening assessment, 12 (11%) could not be reached via phone, and 10 (9%) 
refused study participation. Following screening, two patients were found to be ineligible, 
and 83 patients were eligible and consented to participate.
Eighty patients (96%) completed the standardized phone assessment. Patients who had a 
usual level of 4 or higher on a 0 to 10 scale for anxiety, sadness, sleep problems, pain, or 
fatigue on the PCOQ (Robinson et al., 2005) were invited to participate in the qualitative 
interview. After 25 patients had completed the interview, the research team determined that 
thematic saturation had been reached. Saturation is the point at which no new narrative 
content codes are observed in the data, and further interviews are not expected to change the 
content codes or interpretation of the data.
Table 1 shows demographic and medical characteristics of the sample as well as means and 
standard deviations for severity and importance of the five symptoms. Patients were, on 
average, 54 years old, married, Caucasian, and college-educated (mean = 15 years of 
education). Patients were, on average, 2 years from a stage IV breast cancer diagnosis. On 
average, patients experienced mild levels of anxiety and sadness and moderate levels of 
sleep problems, pain, and fatigue. The average importance ratings for sleep problems, pain, 
and fatigue were slightly higher than those for anxiety and sadness (8 vs. 6, respectively, on 
a 0 to 10 scale).
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Findings
Our thematic analysis identified five sets of interrelated factors underlying MBC patients’ 
perceptions of symptom importance: activity restriction, concentration difficulties, 
exacerbation of other physical symptoms, symptom-related long-term health concerns, and 
negative impact on their relationships with others. Each of these factors is described below.
Activity restriction—The majority of patients rated symptoms as important because they 
restricted their social, recreational, or work-related activities. More patients described 
physical symptoms (i.e., sleep problems, pain, or fatigue) as restricting their activities more 
than psychological symptoms (i.e., anxiety or sadness). One patient noted her 
disengagement from valued activities when experiencing severe pain:
I used to be extremely active so obviously cancer changes you . . . when the pain is 
really bad then I can’t work in the garden. I can’t take my grandbabies out on the 
bike. I can’t power walk. I can’t play tennis. I can’t do the things that are just 
me . . . I’m notorious for a clean home so the pain levels definitely can hinder my 
cleaning, my cooking.
Another patient described how severe fatigue had restricted her activities:
I can’t do all the things I like to do normally . . . . Doing things for the kids or even 
just going to a concert is a big ordeal. To go eat in a restaurant --I don’t even like 
doing that anymore because I get too tired of waiting . . . So being tired doesn’t 
allow me to do any of the things I normally do. I mean I really sit in a chair all day. 
That’s not really what I like to be doing.
Psychological symptoms were also found to be restrictive. One patient characterized her 
anxiety as an “overwhelming feeling” that resulted in social withdrawal:
If I’m feeling really anxious I don’t feel like going out of the house. I prefer to just 
stay home.
Concentration difficulties—Other patients perceived sleep problems, pain, or fatigue as 
important because of their negative effects on concentration. As one patient with severe 
fatigue stated:
My dad just asked me yesterday what I was reading. I said I don’t have the 
attention span to read books anymore. I think it’s better if I just read news articles 
instead because I just fall asleep.
Although patients did not associate sadness with concentration deficits, several patients 
described how anxiety had produced these deficits. As one patient stated:
Anxiety has dominated my life. Anxiety about the cancer and all aspects of 
treatment or side effects, or . . . my life span. All those things have controlled my 
thoughts and it distracts me from enjoying my day, or enjoying my life . . . when I 
get distracted with my thoughts, I don’t hear what other people are saying. It’s hard 
to hold on to conversations. It’s hard interacting with other people and . . . 
interacting with what’s around me, things I enjoy doing.
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Exacerbation of other physical symptoms—Some patients viewed sleep problems 
and pain as treatment priorities because they exacerbated other symptoms. One patient noted 
that “pain interferes with sleep, which then causes fatigue.” Another patient found that 
severe pain led to unwanted weight loss:
I love to cook. I cook from scratch. When I’m hurting real bad I can’t. And if I 
don’t cook, I’m not eating. If I’m not eating, I’m losing weight.
Conversely, fatigue, anxiety, and sadness were not described as precipitants of physical 
symptoms.
Symptom-related long-term health concerns—Some patients were concerned about 
the long-term health implications of sleep problems, pain, or fatigue when rating them as 
treatment priorities. For example, a few patients perceived pain as a sign that the cancer 
might be metastasizing. As one patient stated:
In the affected area where the breast cancer is located, it concerns me as to whether 
it [the pain] is being contained in that same spot, or if it’s moving on to another 
area . . . Any other pain does not bother me; I think the cancer is one pain that I’m 
worrisome with.
Other patients were concerned that they would develop a chronic pain condition that would 
be poorly managed:
The main thing about the pain I’ve experienced so far is the stress level and fear 
factor of this being the beginning of a pain that won’t go away and that won’t be 
controlled. So it’s more like uh-oh, is this it? Is this the one that’s never going to go 
away? So it increases stress and anxiety thinking what if this is here forever.
Another health concern was the impact of sleep disturbance on bodily function. One patient 
stated:
It’s really important to have a good sleep pattern in order for your body to sustain 
itself and to help itself heal.
Negative impact on relationships with others—Lastly, some patients prioritized 
symptoms which were thought to negatively impact their relationships with others. For 
example, several patients noted their increased irritability when experiencing sleep problems 
or pain. One patient described how her pain affected her parenting:
I have two young children, and I get very irritated when I’m in severe pain, so I 
tend to not have any patience.
The negative effects of sadness and anxiety on social demeanour were also discussed. One 
patient noted her social disengagement that accompanied sadness:
It was difficult to really listen--enjoy other people and everyday things because all I 
could think about was my cancer and how sad it made me and I just didn’t feel--
people would be talking about their lives and what’s going on, but I just felt like I 
was on the outside, not participating.
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DISCUSSION
This study provides rich, descriptive information on factors driving the perceived importance 
of reducing specific symptoms in a symptomatic advanced cancer patient sample. MBC 
patients with at least one moderate to severe symptom (i.e., anxiety, sadness, sleep problems, 
pain, or fatigue) were asked to share the thoughts they had while determining symptom 
treatment priorities. The most common reason for symptom importance was its detrimental 
impact on activities. Impairments in daily activities and work productivity are highly 
prevalent in MBC patients and are associated with increased symptom burden (Cleeland et 
al., 2014; Low & Stanton, 2015). Moreover, research suggests that activity disruption is a 
major source of reduced enjoyment of life among MBC patients (Low & Stanton, 2015). 
The present findings connect this work to the clinical care setting by suggesting that MBC 
patients prioritize the treatment of symptoms that interfere with valued activities.
Some patients noted the long-term health implications of symptoms when asked to discuss 
their importance. For example, several patients viewed pain as a treatment priority due to its 
potential association with progressive metastatic disease. Fear of metastases is a common 
concern among MBC and other advanced cancer patients (Aranda et al., 2005; Voogt et al., 
2005), and the present results suggest that this fear may lead some MBC patients to place a 
greater emphasis on pain reduction. Other patients prioritized pain reduction due to concern 
that they would develop a chronic, poorly controlled pain condition. Finally, some patients 
believed that a lack of sleep would impede healing processes and, therefore, rated sleep 
disruption as particularly important.
In addition to concerns about the downstream health effects of symptoms and their effect on 
activities, social factors appeared to influence MBC patients’ prioritization of physical and 
psychological symptoms. Specifically, some patients noted their increased irritability or poor 
listening skills during conversations with close others when symptomatic. In a prior survey, 
concerns about loved ones were among the most common psychological needs of MBC 
patients (Aranda et al., 2005), and our findings suggest that the desire to maintain a positive 
social demeanour may underlie patients’ emphasis on managing certain symptoms.
Other reasons that symptoms were viewed as treatment priorities included their negative 
effects on concentration. Although few studies have examined cognitive functioning in MBC 
patients (Aranda et al., 2005; Bender et al., 2005; Mayer, 2010), preliminary evidence 
suggests that concentration difficulties are associated with greater fatigue and other 
symptoms in this population (Bender et al., 2005). Additionally, in the current study, some 
patients considered pain or sleep disturbance to be treatment priorities because of their 
compounding effect on other symptoms (e.g., weight loss, fatigue). The detrimental impact 
of symptom co-occurrence on functional status and quality of life has been documented in 
patients with various cancers (Fan et al., 2007; Given et al., 2007). Thus, it is not surprising 
that MBC patients prioritized the treatment of symptoms that appeared to exacerbate other 
symptoms.
Limitations of the current study and directions for future research warrant mention. The 
sample primarily consisted of college-educated Caucasian patients. Further research is 
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needed to determine the transferability of study findings to diverse socioeconomic and 
ethnic groups. Additionally, this study focused on five of the most common and distressing 
symptoms for MBC patients; identifying factors underlying judgments of symptom 
importance for other symptoms (e.g., nausea, lymphedema) would expand the current 
analysis. Finally, longitudinal research would allow us to gain a better understanding of 
factors driving judgments of symptom importance at difference phases of the disease 
trajectory (e.g., diagnosis, treatment, and end-of-life).
Findings have a number of implications for intervention research and clinical practice with 
MBC patients. First, findings suggest that clinicians should assess the impact of specific 
symptoms on daily activities and functioning when determining treatment priorities. 
Additionally, the meaning of symptoms from the patient’s perspective should be assessed. 
This information would inform patient-centred approaches to symptom-related education 
and treatment. For example, patients who interpret pain as a sign of disease metastases and 
therefore prioritize pain management might benefit from cognitive-behavioural approaches 
that gently challenge these beliefs. Other patients may prioritize symptoms that interfere 
with valued activities. These patients may benefit from Acceptance and Commitment 
therapy (ACT), which encourages a more flexible and meaningful way of living that is not 
governed by symptom intensity (Hulbert-Williams et al., 2015). Finally, results suggest that 
clinicians should assess MBC patients’ perceptions of symptom importance and factors 
underlying these perceptions—not just symptom severity and frequency. For example, a 
checklist to rank symptoms in order of importance may facilitate shared treatment decision-
making between the patient and provider. Given the high symptom burden of MBC patients, 
identifying their priorities for symptom improvement and beliefs underlying these priorities 
may optimize health care quality and their satisfaction and engagement in health care.
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Table 1
Sample characteristics (N = 25)
Characteristic n (%) Mean (SD) Range
Age, years 54 (11) 33 to 69
Race
 Caucasian 22 (88%)
 African American 2 (8%)
 Other 1 (4%)
Education, years 15 (2) 12 to 19
Employment status
 Employed 4 (16%)
 Not employed 21 (84%)
Marital status
 Married or marriage equivalent 13 (52%)
 Not married 12 (48%)
Time since diagnosis of Stage IV breast cancer, years 2 (2) 0 to 7
Type of breast cancer treatment
 Mastectomy 18 (72%)
 Lumpectomy 5 (20%)
 Chemotherapy 22 (88%)
 Radiation 14 (56%)
 Targeted therapy 14 (56%)
 Hormonal therapy 18 (72%)
Usual symptom levelsa
 Anxiety 2 (2) 0 to 8
 Sadness 2 (3) 0 to 8
 Sleep problems 4 (2) 0 to 7
 Pain 3 (3) 0 to 9
 Fatigue 5 (2) 2 to 10
Perceived symptom importanceb
 Anxiety 6 (4) 0 to 10
 Sadness 6 (4) 0 to 10
 Sleep problems 8 (3) 0 to 10
 Pain 8 (3) 0 to 10
 Fatigue 8 (2) 3 to 10
SD = standard deviation.
a
Each symptom was rated on a scale from 0 (none) to 10 (worst imaginable).
b
Each symptom was rated on a scale from 0 (not at all important) to 10 (most important).
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